

Ref: FOI/GS/ID 7412

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

17 June 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Incidents of Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL).

You asked:

Q1. How many patients has your trust treated in the past 3 months for the following conditions:

- a. Chronic Lymphocytic Leukaemia (CLL)*
- b. Mantle Cell Lymphoma (MCL)*
- c. In case you do not treat either of the above conditions, please tell us which trust or hospital you refer patients to.*

Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:

- a. BR (bendamustine + rituximab)*
- b. Calquence (acalabrutinib)*
- c. FCR (fludarabine + cyclophosphamide + rituximab)*
- d. Gazyva (obinutuzumab) + chlorambucil*
- e. Imbruvica (ibrutinib)*
- f. Venclexta (venetoclax)*
- g. Venclexta (venetoclax) + Gazyva (obinutuzumab)*
- h. Venclexta (venetoclax) + rituximab*
- i. Zydelig (idelalisib) + rituximab*
- j. Any other systemic anti-cancer therapy*

Q3. How many Mantle Cell Lymphoma (MCL) patients have been treated in the past 3 months with the following:

- a. BR (bendamustine + rituximab)*
- b. Imbruvica (ibrutinib)*
- c. Imbruvica (ibrutinib) + rituximab*
- d. R-BAC (rituximab, bendamustine and cytarabine)*

- e. R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone)
- f. Nordic Protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, cytarabine & prednisolone)
- g. Velcade (bortezomib) + chemotherapy
- h. Any other systemic anti-cancer therapy
- i. Stem cell transplant
- j. Tecartus (CAR-T) - Autologous anti-CD19-transduced CD3+ cells

Q4. Does your trust currently participate in any ongoing clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL)? If so, can you please provide the name of each trial along with the number of patients taking part?

Q5. Does your trust currently participate in any ongoing clinical trials for the treatment of Mantle Cell Lymphoma (MCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

Trust response:

Q1.

- a) 55 patients, 54 patients have received SACT with radical intent and 1 patient has received radiotherapy for metastatic disease.
- b) 9 patients had received SACT and 1 has received radiotherapy to mediastinal disease.
- c) Not applicable

Q2.

- a. 0
- b. 22
- c. 0
- d. 0
- e. 8
- f. 15
- g. 8
- h. 1
- i. 0
- j. 0

Q3.

a.	0
b.	5
c.	1
d.	0
e.	1
f.	1
g.	0
h.	1

i.	The Trust does not undertake this treatment.
j.	The Trust does not undertake this treatment.

Q4. The Trust does not currently have any studies open for CLL patients.

Q5. The Trust does not have an open study at present.